ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

HVO Hvivo Plc

27.75
0.50 (1.83%)
Last Updated: 14:49:29
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo Plc LSE:HVO London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 1.83% 27.75 27.50 28.00 27.75 27.25 27.25 766,365 14:49:29
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 56.04M 16.12M 0.0237 11.65 185.4M

hVIVO plc Result of AGM (0179Z)

23/05/2016 12:00pm

UK Regulatory


Hvivo (LSE:HVO)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Hvivo Charts.

TIDMHVO

RNS Number : 0179Z

hVIVO plc

23 May 2016

For immediate release 12.00pm: 23 May 2016

HVIVO PLC

("hVIVO" or the "Company")

Result of Annual General Meeting

hVIVO plc (AIM: RVG), the pioneer of human models of disease, is pleased to announce that all resolutions proposed at its Annual General Meeting, held at 10.00am on 23 May 2016, were duly passed.

For further information please contact:

hVIVO plc +44 207 756 1300

Kym Denny (Chief Executive Officer)

Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries +44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, RSV, asthma and common cold. hVIVO has commercialised four disease models, successfully enrolled over 2,000 subjects and conducted over 40 product validation studies for a wide range of industry, government and academic clients and collaborators.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGAKNDNKBKDQPB

(END) Dow Jones Newswires

May 23, 2016 07:00 ET (11:00 GMT)

1 Year Hvivo Chart

1 Year Hvivo Chart

1 Month Hvivo Chart

1 Month Hvivo Chart

Your Recent History

Delayed Upgrade Clock